Last reviewed · How we verify

NCT06207227

Clinical Performance and Safety of the VITA AV Clinical System

Completed NA Last updated 17 December 2024
What this trial tests

NA trial testing VITA AV Clinical System in Vaginal Atrophy in 12 participants. Completed in 25 September 2024.

Timeline
13 April 2023
Primary endpoint
20 October 2023
25 September 2024

Quick facts

Lead sponsorAVeta Medical
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment12
Start date13 April 2023
Primary completion20 October 2023
Estimated completion25 September 2024
Sites1 location across Georgia

Drugs / interventions tested

Conditions studied

Sponsor

AVeta Medical

Who can join

Adults 51 to 70, female only, with Vaginal Atrophy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this clinical investigation is to demonstrate that treatment with the VITA AV clinical system is feasible and to evaluate clinical performance and safety when used to improve the symptoms and signs of vaginal atrophy (VA) due to menopause.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Vaginal Atrophy

Currently open trials in the same condition.

Other AVeta Medical trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06207227.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing